Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...
Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...
Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...
Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.
The international community will celebrate World Tuberculosis Day on Monday, 24 March this year. The theme for 2025 is “Yes!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback